Copyright
©The Author(s) 2018.
World J Gastroenterol. Jun 21, 2018; 24(23): 2457-2467
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2457
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2457
Figure 1 Vedolizumab targets the α4β7 integrin, preventing leucocyte translocation from the blood into the inflamed gut tissue.
MadCAM-1: Mucosal addressin cell adhesion molecule.
Figure 2 Real-world studies with vedolizumab in patients with ulcerative colitis (A) and Crohn’s disease (B): Results at week 14.
- Citation: Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467
- URL: https://www.wjgnet.com/1007-9327/full/v24/i23/2457.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i23.2457